New drug duo aims to rally immune system against tough brain cancers
Disease control
Recruiting now
This study is testing whether combining an oral vitamin A-based drug (ATRA) with an immunotherapy (retifanlimab) can help control a specific type of recurrent brain tumor called IDH-mutant glioma. It aims to see if this combination is safe and can stimulate the patient's own immu…
Phase: PHASE2 • Sponsor: Stephen Bagley, MD, MSCE • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC